



# 2023 American Society of Hematology (ASH) Annual Conference

---

TAKEDA SPONSORED ABSTRACTS

# HEMATOLOGY

ABSTRACT #

TITLE

SESSION

## CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA

### [ABSTRACT 692](#)

Recombinant ADAMTS13 for the Treatment of Acute TTP Events in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Controlled, Crossover Study and the Phase 3b Continuation Study

#### ORAL PRESENTATION

**Session 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: New Frontiers in TTP: Diagnostic and Therapeutic Innovations**

December 11, 2023  
10:30 AM – 12:00 PM PST

Location: San Diego Convention Center, Room 29



### [ABSTRACT 1260](#)

Population Pharmacokinetics and Exposure Response Analyses to Demonstrate the Link of Causality Between ADAMTS13 and the Clinical Effects of Recombinant ADAMTS13 Compared to Plasma-Based Therapies

#### POSTER PRESENTATION

**Session 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I**

December 9, 2023  
5:30 – 7:30 PM PST

Location: San Diego Convention Center, Halls G-H



### [ABSTRACT 2366](#)

Preferences of Patients with Congenital Thrombotic Thrombocytopenic Purpura and Other Chronic Conditions for in-Home Prophylactic Infusions

#### POSTER PRESENTATION

**Session 904. Outcomes Research Non-Malignant Conditions: Poster I**

December 9, 2023  
5:30 – 7:30 PM PST

Location: San Diego Convention Center, Halls G-H

### [ABSTRACT 4006](#)

Clinical Outcomes of Congenital Thrombotic Thrombocytopenic Purpura: A Multinational Chart Review Study

#### POSTER PRESENTATION

**Session 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster III**

December 11, 2023  
6:00 – 8:00 PM PST

Location: San Diego Convention Center, Halls G-H

### [ABSTRACT 1261](#)

Pregnancy-Related Outcomes in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of a Retrospective Chart Review Study

#### POSTER PRESENTATION

**Session 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I**

December 9, 2023  
5:30 – 7:30 PM PST

Location: San Diego Convention Center, Halls G-H

ABSTRACT #

TITLE

SESSION

**SICKLE CELL DISEASE (SCD)**[ABSTRACT  
149](#)

Safety And Pharmacokinetics of Recombinant ADAMTS13 in Patients with Sickle Cell Disease: A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study

**ORAL PRESENTATION**

**Session 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Hot Topics in Clinical Care and Genomic Factors**

December 9, 2023  
2:00 - 3:30 PM PST

Location: San Diego Convention Center,  
Room 31

**HEMOPHILIA A**[ABSTRACT  
283](#)

Clinical Outcomes of Noninhibitor Patients with Hemophilia A Switching from Prophylaxis with Factor VIII to Emicizumab: A Meta-Analysis of Real-World Evidence Studies

**ORAL PRESENTATION**

**Session 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Beyond the Numbers: Non-Factor Factors in Bleeding Disorder Care**

December 9, 2023  
4:00 - 5:30 PM PST

Location: San Diego Convention Center,  
Room 30

[ABSTRACT  
3742](#)

Identifying Ideal Individuals for PK-Guided Dosing; Recreational Risks and Elevated Breakthrough Bleeding

**POSTER PRESENTATION**

**Session 904. Outcomes Research Non-Malignant Conditions: Poster II**

December 10, 2023  
6:00 - 8:00 PM PST

Location: San Diego Convention Center,  
Halls G-H

**VON WILLEBRAND DISEASE**[ABSTRACT  
2613](#)

Real-World Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of ATHN 9: A Natural History Study For People With Severe VWD

**POSTER PRESENTATION**

**Session 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II**

December 10, 2023  
6:00 - 8:00 PM PST

Location: San Diego Convention Center,  
Halls G-H



# ONCOLOGY

ABSTRACT #

TITLE

SESSION

## HODGKIN LYMPHOMA

[ABSTRACT  
1713](#)

The Comparative Effectiveness of A+AVD vs PET-guided ABVD for the Management of Patients with Advanced Hodgkin Lymphoma: A Systematic Review and Matching-Adjusted Indirect Treatment Comparison

**POSTER PRESENTATION**

**Session 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I**

December 9, 2023  
5:30 – 7:30 PM PST

Location: San Diego Convention Center,  
Halls G-H



[ABSTRACT  
3057\\*](#)

Comprehensive Analysis of Treatment Related Morbidity and Progression-free Survival in the GSHG Phase III HD21 Trial

**POSTER PRESENTATION**

**Session 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II**

December 10, 2023  
6:00 – 8:00 PM PST

Location: San Diego Convention Center,  
Halls G-H

## LEUKEMIA

[ABSTRACT  
2871](#)

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 PhALLCON Study

**POSTER PRESENTATION**

**Session 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II**

December 10, 2023  
6:00 – 8:00 PM PST

Location: San Diego Convention Center,  
Halls G-H



[ABSTRACT  
3164](#)

Long-term Results from the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

**POSTER PRESENTATION**

**Session 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II**

December 10, 2023  
6:00 – 8:00 PM PST

Location: San Diego Convention Center,  
Halls G-H

\*Study to be presented by the German Hodgkin Study Group (GSHG)

ALL PRODUCTS ARE INVESTIGATIONAL IN THE SETTING IN WHICH THEY ARE CURRENTLY BEING STUDIED AND NOT APPROVED FOR THESE INDICATIONS, SAFETY AND EFFICACY NOT YET ESTABLISHED.



| ABSTRACT # | TITLE | SESSION |
|------------|-------|---------|
|------------|-------|---------|

## PIPELINE

### [ABSTRACT 349](#)

Role of Cell Therapy Product Characteristics in Patient Response to TAK-940 (CD19(T2)28z1xx Chimeric Antigen Receptor (CAR) T): Biomarker analyses from a Phase I Study in Adult Patients with Relapsed or Refractory B-cell Malignancies

### ORAL PRESENTATION

**Session 703. Cellular Immunotherapies: Basic and Translational: Cellular Immunotherapy: Preclinical and Translational Insights**

December 9, 2023  
4:00 – 5:30 PM PST

Location: San Diego Convention Center,  
Room 6A



### [ABSTRACT 3316](#)

Modakafusp Alfa Demonstrates Type I Interferon-Mediated Innate and Adaptive Immune Enhancement in a Phase 1/2 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

### POSTER PRESENTATION

**Session 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational**

December 10, 2023  
6:00 – 8:00 PM PST

Location: San Diego Convention Center,  
Halls G-H



For more information, please see [ASH online program](#).